Recent Publication Highlights Proof-of-Concept Data Supporting the…

TUSTIN, Calif., Feb. 09, 2017 — Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform. Results of the study, conducted at University of Texas Southwestern Medical Center, showed researchers were able to distinguish between healthy subjects and patients with ovarian tumors based on the levels of exosomes containing phosphatidylserine found in their plasma.